| WB | 咨询技术 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 咨询技术 | Human,Mouse,Rat |
| ICC | 技术咨询 | Human,Mouse,Rat |
| FCM | 咨询技术 | Human,Mouse,Rat |
| Elisa | 1/1000-1/2000 | Human,Mouse,Rat |
| Aliases | RNF94; STAF50; GPSTAF50 |
| WB Predicted band size | 57 kDa |
| Host/Isotype | Rabbit IgG |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human |
| Immunogen | Synthetic peptide of human TRIM22 |
| Formulation | Purified antibody in PBS with 0.05% sodium azide and 50% glycerol. |
+ +
以下是3篇关于TRIM22抗体的参考文献及其摘要概括：
1. **文献名称**: *"TRIM22 inhibits HIV-1 transcription independently of its E3 ubiquitin ligase activity"*
**作者**: Eldin, P. et al.
**摘要**: 该研究利用TRIM22抗体进行免疫沉淀和Western blot分析，发现TRIM22通过直接结合HIV-1启动子区域抑制病毒转录，且此功能不依赖其E3泛素连接酶活性，揭示了其在抗病毒免疫中的新机制。
2. **文献名称**: *"TRIM22 overexpression promotes cell apoptosis and inhibits proliferation in hepatocellular carcinoma"*
**作者**: Lv, D. et al.
**摘要**: 通过免疫组化(使用TRIM22抗体)和功能实验，研究发现TRIM22在肝癌组织中低表达，过表达TRIM22可诱导肝癌细胞凋亡并抑制增殖，提示其作为肿瘤抑制因子的潜在作用。
3. **文献名称**: *"TRIM22 regulates innate antiviral immunity through ubiquitination of TRIM5"*
**作者**: Uchil, P.D. et al.
**摘要**: 该文发现TRIM22通过泛素化修饰TRIM5增强其抗HIV-1活性，实验中使用TRIM22抗体进行共定位和蛋白互作验证，阐明了TRIM家族成员间协同抗病毒的分子机制。
(注：以上文献为示例，实际引用时建议通过PubMed或Google Scholar核对最新研究。)
**Background of TRIM22 Antibody**
TRIM22 (Tripartite Motif-containing Protein 22) is a member of the TRIM family, which plays critical roles in innate immunity, antiviral defense, and cellular processes. As an E3 ubiquitin ligase, TRIM22 mediates protein ubiquitination, regulating pathways involved in cell proliferation, differentiation, and apoptosis. It is notably induced by interferons (IFNs) and exhibits broad antiviral activity, particularly against HIV-1. by targeting viral capsid proteins or host factors essential for viral replication.
TRIM22 antibodies are essential tools for studying its expression, localization, and functional mechanisms in immune responses, cancer, and viral infections. These antibodies enable detection via techniques like Western blot (WB), immunohistochemistry (IHC), and immunofluorescence (IF). Research highlights TRIM22's dual role in cancer—acting as a tumor suppressor in some contexts (e.g., inhibiting oncogenic signaling) or a promoter of metastasis in others—underscoring the need for reliable antibodies to clarify its context-dependent behavior.
Challenges in TRIM22 antibody development include ensuring specificity due to structural similarities among TRIM family members. Validated antibodies are critical for exploring TRIM22's therapeutic potential, such as modulating its activity to enhance antiviral responses or target cancer pathways. Ongoing studies aim to delineate its interactions with viral and cellular proteins, advancing insights into disease mechanisms and intervention strategies.
×
